• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. von Eschenbach steps down from NCI post; Dr. Niederhuber appointed

Article

John Niederhuber, MD, has been designated to serve as acting director of the National Cancer Institute. Andrew von Eschenbach, MD, formally submitted his resignation as NCI director and will continue to serve as acting FDA commissioner.

John Niederhuber, MD, has been designated to serve as acting director of the National Cancer Institute. Andrew von Eschenbach, MD, formally submitted his resignation as NCI director and will continue to serve as acting FDA commissioner.

Dr. Niederhuber joined the National Institutes of Health in 2005 as NCI’s deputy director for translational and clinical sciences. Immediately before his recruitment to NCI, he chaired the National Cancer Advisory Board. His extensive academic and research career in the field of cancer has included positions at the University of Michigan, Johns Hopkins University, Stanford University, and, most recently the University of Wisconsin.

Dr. von Eschenbach, a urologist, was appointed by President Bush to head the NCI in January 2002. He has served as acting FDA commissioner since September 2005.

Related Videos
Jenny Guo, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Samuel L. Washington III, MD, MAS, answers a question during a Zoom video interview
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Leo Dreyfuss, MD, answers a question during a Zoom video interview
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
© 2024 MJH Life Sciences

All rights reserved.